Core Insights - Integra LifeSciences Holdings Corporation reported a GAAP net loss of $(1.7) million for Q4 2025, a significant decline from a net income of $19.4 million in Q4 2024, reflecting operational challenges and a goodwill impairment charge [5][14] - The company generated total revenues of $434.9 million in Q4 2025, a decrease of 1.7% from the same quarter in 2024, with organic revenues down 2.5% [5][9] - For the full year 2025, total reported revenues were $1,635.2 million, an increase of 1.5% compared to 2024, but organic sales decreased by 0.7% [9][13] Fourth Quarter 2025 Financial Summary - Total reported revenues for Q4 2025 were $434.9 million, down 1.7% from Q4 2024, with organic revenues decreasing by 2.5% [5][9] - The company reported a GAAP net loss of $(1.7) million, or $(0.02) per diluted share, compared to a net income of $19.4 million, or $0.25 per diluted share in Q4 2024 [5][9] - Adjusted EBITDA for Q4 2025 was $104.2 million, slightly down from $104.9 million in Q4 2024, with an adjusted EBITDA margin of 24.0% [6][9] Full-Year 2025 Financial Summary - Total reported revenues for the full year 2025 were $1,635.2 million, an increase of 1.5% from 2024, while organic sales decreased by 0.7% [9][13] - The company reported a GAAP net loss of $(516.5) million, or $(6.74) per diluted share, primarily due to a $511 million goodwill impairment charge [14][15] - Adjusted net income for the full year 2025 was $171.4 million, or $2.23 per diluted share, compared to $196.9 million, or $2.56 per diluted share in 2024 [15][9] Segment Performance - Codman Specialty Surgical, which accounts for 75% of revenues, reported total revenues of $323.3 million in Q4 2025, an increase of 2.7% on a reported basis [10][9] - Tissue Technologies, representing 25% of revenues, saw total revenues decline by 12.8% in Q4 2025, reflecting challenges in the Wound Reconstruction segment [12][9] Cash Flow and Capital Allocation - Cash flows from operations totaled $11.8 million in Q4 2025, with capital expenditures of $17.2 million [7][9] - For the full year 2025, the company generated cash flow from operations of $50.4 million, with capital expenditures amounting to $81.4 million [16][9] 2026 Guidance - For the full year 2026, the company expects revenues to range from $1,662 million to $1,702 million, indicating reported growth of 1.6% to 4.1% and organic growth of 0.8% to 3.3% [17][18] - Adjusted earnings per diluted share for 2026 are projected to be between $2.30 and $2.40 [17][18]

Financial Performance - Q2 2025 revenue was $415.6 million, a decrease of 0.6% compared to Q2 2024's $418.2 million[37] - Organic revenue decreased by 1.4% to $412.4 million in Q2 2025 compared to $418.2 million in Q2 2024[9, 38] - Adjusted EPS for Q2 2025 was $0.45, a decrease of 28.6% compared to $0.63 in Q2 2024[10, 37] - Adjusted EBITDA margin decreased by 290 bps to 17.1% in Q2 2025 compared to 20.0% in Q2 2024[10, 40] - Adjusted gross margin decreased by 450 bps to 60.7% in Q2 2025 compared to 65.2% in Q2 2024[11, 37] - Operating cash flow was $8.9 million with a negative 32.7% free cash flow conversion in Q2 2025[11, 39] Segment Performance - Codman Specialty Surgical Q2 2025 revenue was $304.0 million, a 0.7% increase, with organic growth down 0.3% to $300.9 million[13] - Tissue Technologies Q2 2025 revenue was $111.6 million, a decrease of 4.1%[18] Guidance - Q3 2025 reported revenue is projected to be between $410 million and $420 million, with organic growth between +7.3% and +9.9%[28] - Full year 2025 reported revenue is projected to be between $1.655 billion and $1.680 billion, with organic growth between +0.6% and +2.1%[29, 30]

Core Insights - Integra LifeSciences Holdings Corporation reported a total revenue of $415.6 million for Q2 2025, reflecting a decrease of 0.6% on a reported basis and 1.4% on an organic basis compared to the previous year [5][9] - The company experienced a GAAP net loss of $484.1 million, or $6.31 per diluted share, primarily due to a goodwill impairment charge of $511 million [6][9] - Adjusted net income for the quarter was $34.4 million, or $0.45 per diluted share, down from $49.0 million, or $0.63 per diluted share, in the prior year [6][9] Financial Performance - Total reported revenues decreased to $415.6 million, with a GAAP gross margin of 50.4%, down from 54.0% in Q2 2024 [5][6] - Adjusted gross margin was 60.7%, compared to 65.2% in the prior year [5][6] - Adjusted EBITDA for Q2 2025 was $71.2 million, representing 17.1% of revenue, down from $83.8 million, or 20.0% of revenue, in the prior year [5][6] Segment Performance - Codman Specialty Surgical, which accounts for approximately 70% of revenues, reported total revenues of $304.0 million, showing a reported growth of 0.7% but an organic decline of 0.3% compared to Q2 2024 [7] - Tissue Technologies, making up about 30% of revenues, saw total revenues of $111.6 million, reflecting a reported and organic decline of 4.1% compared to the same quarter last year [11] Operational Updates - The company has completed the assessment phase at all manufacturing sites as part of its Compliance Master Plan and is focused on remediation efforts [4] - Cash flow from operations for the quarter was $8.9 million, with total balance sheet debt at $1.85 billion and net debt at $1.59 billion [11][12] Guidance and Outlook - For Q3 2025, the company expects reported revenues in the range of $410 million to $420 million, indicating reported growth of 7.7% to 10.3% and organic growth of 7.3% to 9.9% [13] - The full-year revenue guidance has been updated to a range of $1.655 billion to $1.680 billion, representing reported growth of 2.8% to 4.3% and organic growth of 0.6% to 2.1% [14]